Moderna Inc (MRNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Moderna Inc (MRNA) has a cash flow conversion efficiency ratio of 0.110x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($951.00 Million) by net assets ($8.65 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Moderna Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Moderna Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Moderna Inc debt and liabilities for a breakdown of total debt and financial obligations.
Moderna Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moderna Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OMV AG ADR 1
F:OMVI
|
N/A |
|
B3 S.A. - Brasil Bolsa Balcão
SA:B3SA3
|
0.081x |
|
OMV Aktiengesellschaft
VI:OMV
|
0.074x |
|
Suncorp Group Ltd
AU:SUNPH
|
-0.042x |
|
Global Unichip Corp
TW:3443
|
-0.021x |
|
Bombardier Inc
TO:BBD-B
|
-0.173x |
|
Tyson Foods Inc
NYSE:TSN
|
0.052x |
|
InterGlobe Aviation Limited
NSE:INDIGO
|
1.250x |
Annual Cash Flow Conversion Efficiency for Moderna Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Moderna Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see MRNA stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.65 Billion | $-1.87 Billion | -0.217x | +21.42% |
| 2024-12-31 | $10.90 Billion | $-3.00 Billion | -0.276x | -22.44% |
| 2023-12-31 | $13.85 Billion | $-3.12 Billion | -0.225x | -186.41% |
| 2022-12-31 | $19.12 Billion | $4.98 Billion | 0.260x | -72.95% |
| 2021-12-31 | $14.14 Billion | $13.62 Billion | 0.963x | +21.66% |
| 2020-12-31 | $2.56 Billion | $2.03 Billion | 0.791x | +302.59% |
| 2019-12-31 | $1.17 Billion | $-458.97 Million | -0.391x | -80.69% |
| 2018-12-31 | $1.53 Billion | $-330.87 Million | -0.216x | +59.21% |
| 2017-12-31 | $625.30 Million | $-331.48 Million | -0.530x | -768.75% |
| 2016-12-31 | $841.85 Million | $66.73 Million | 0.079x | +100.97% |
| 2015-12-31 | $90.19K | $-738.15K | -8.185x | -848.61% |
| 2014-12-31 | $-4.37 Million | $-4.78 Million | 1.093x | -- |
About Moderna Inc
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses incl… Read more